Fish Oil (Omega-3): What the Research Says

What Is Fish Oil

Fish oil provides two key omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These are long-chain polyunsaturated fats that the body cannot efficiently synthesize from plant-based omega-3s (ALA). EPA is the primary anti-inflammatory and mood-related omega-3, while DHA is a structural component of brain and retinal tissue.

The average Western diet provides roughly 100-200 mg of EPA+DHA daily -- well below the 250-500 mg minimum recommended by most health organizations, and far below the 2-4 g therapeutic doses used in clinical trials for triglyceride reduction and mood disorders.

What the Evidence Shows

Condition	Evidence	Key Finding	Dose
Triglycerides	Strong	High-dose: -57 mg/dL long-term, -51 mg/dL short-term. Dose-dependent and highly reproducible.[1]	2-4 g/day
Anxiety	Moderate	Dose-response: each 1 g EPA+DHA = SMD -0.70. Optimal at 2 g/day (23 RCTs).[2]	2 g/day EPA+DHA
Depression	Moderate	SMD -0.26 across 36 RCTs. EPA intake linearly correlated with remission. Best: 1-1.5 g/day, EPA:DHA 1:1 to 2:1.[3]	1-1.5 g/day EPA-dominant
Inflammation	Moderate	Consistent CRP reduction. In hemodialysis patients: SMD -0.62 for CRP (strongest at lower doses).[4]	2-3 g/day
Cardiovascular	Moderate	Triglyceride reduction is clear and dose-dependent. Overall CVD mortality data remains mixed across trials.	2-4 g/day
Sleep efficiency	Limited	Significantly higher sleep efficiency vs control across 8 RCTs.[5]	0.6-4 g/day
Weight loss	Insufficient	21 studies found no effect on body weight in overweight/obese adults.[6]	Not effective

Deep Dives

EPA vs DHA: Which Matters More

EPA and DHA are often lumped together, but they have distinct roles in the body. The evidence suggests which one to prioritize depends on the goal:

Goal	Prioritize	Rationale
Depression/anxiety	EPA-dominant (EPA:DHA of 2:1 or higher)	EPA intake linearly correlates with depression remission rate; EPA drives the anti-inflammatory cascade relevant to mood[3]
Triglycerides	Combined EPA+DHA (high-dose)	Both EPA and DHA lower triglycerides; high total dose matters most[1]
Brain structure/development	DHA-dominant	DHA is the primary structural omega-3 in the brain and retina
General health	Combined EPA+DHA (1:1 to 2:1)	Optimal ratio in the largest depression meta-analysis was 1:1 to 2:1 EPA:DHA[3]

The most important takeaway: total EPA+DHA dose matters more than the ratio for most outcomes. The EPA distinction becomes relevant primarily for mood-related conditions, where EPA-dominant formulations consistently outperform DHA-dominant ones.

Forms Compared: Triglyceride vs Ethyl Ester vs Krill vs Algal

Form	Bioavailability	Best For	Notes
Triglyceride (rTG) fish oil	Highest	General use	Re-esterified natural form. Better absorbed than ethyl esters (up to 70% more). Gold standard.
Ethyl ester (EE) fish oil	Lower	Budget option	Most common form in cheap supplements. Requires fat for absorption. Used in many clinical trials (including Rx Vascepa/Lovaza).
Krill oil	Moderate	Lower-dose use	Phospholipid-bound omega-3s. Better absorbed per mg, but capsules contain far less EPA+DHA (typically 50-100 mg vs 500-1000 mg in fish oil).
Algal oil	Good	Vegetarians/vegans	Sustainable, mercury-free, DHA-rich (some newer formulations include EPA). The only viable plant-based EPA+DHA source.

Practical recommendation: Triglyceride-form fish oil is the best combination of dose, absorption, and value. Ethyl ester works fine if taken with a fat-containing meal. Krill oil is not cost-effective for therapeutic doses (you would need 10-20+ capsules). Algal oil is the right choice for those avoiding animal products.

Quality and Purity

Fish oil quality varies significantly between products. The two primary concerns are oxidation and contaminants:

• Oxidation: Rancid fish oil is common. Check TOTOX (total oxidation) values -- should be below 26 meq/kg. Fishy burps and taste often indicate oxidation, not just the nature of fish oil.
• Mercury and heavy metals: Molecular distillation removes nearly all mercury from refined fish oil. Look for products tested by third-party labs (IFOS, NSF, USP, ConsumerLab).
• EPA+DHA content: A "1000 mg fish oil" capsule often contains only 300 mg EPA+DHA. Always check the actual EPA+DHA content on the supplement facts panel, not just total fish oil.
• Third-party testing: Independent certification (IFOS 5-star, NSF International, USP) verifies potency, purity, and freshness. This matters more for fish oil than most supplements.

Dosing by Goal

Goal	Daily EPA+DHA	Form Preference	Duration
General health	500-1000 mg	Any quality source	Ongoing
Triglyceride reduction	2-4 g	Triglyceride form or Rx	8+ weeks for full effect
Depression/anxiety	1-2 g (EPA-dominant)	EPA:DHA ratio of 2:1+	8+ weeks minimum
Inflammation	2-3 g	Combined EPA+DHA	Ongoing
Sleep	1-2 g	Any quality source	Limited evidence on timeline

Safety and Side Effects

Fish oil is generally well-tolerated, but there are important considerations -- especially at therapeutic doses:

• Fishy burps and aftertaste: The most common complaint. Minimized by enteric-coated capsules, freezing capsules before use, triglyceride-form supplements, and taking with meals. Persistent fishiness may indicate oxidized (rancid) oil.
• GI effects: Nausea, diarrhea, or loose stools can occur at higher doses. Usually resolves by splitting doses across meals.
• Blood thinning: Omega-3s have mild antiplatelet effects at high doses (4+ g/day). Clinically relevant for those on anticoagulants (warfarin, aspirin, DOACs) or before surgery. Discuss with your provider if applicable.
• Immunosuppressant interaction: High-dose omega-3s may amplify immunosuppressive drugs. Monitor if on cyclosporine or similar medications.

The LDL Cholesterol Caveat

This is an important and under-discussed finding: omega-3 supplementation can increase LDL cholesterol, particularly at lower doses. A 2025 meta-analysis of metabolic syndrome trials found:^[1]

• Low-dose, short-term: LDL increased by +7 mg/dL
• Low-dose, long-term: LDL increased by +35.5 mg/dL

This does not negate the triglyceride benefits, but it means fish oil is not a universally "heart-healthy" supplement without nuance. If you have elevated LDL, discuss omega-3 supplementation with your provider and monitor lipid panels. High-dose omega-3s used for triglyceride reduction should be managed alongside overall cardiovascular risk assessment.

References

1. Basirat A, Merino-Torres JF. "Marine-Based Omega-3 Fatty Acids and Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Nutrients. 2025. High-dose TG reduction: -56.78 mg/dL; LDL increase at low doses: +35.5 mg/dL. PubMed
2. Su KP, et al. "Omega-3 fatty acids for anxiety: dose-response meta-analysis." 23 RCTs. Each 1 g EPA+DHA = SMD -0.70. 2024. PubMed
3. Kong L, et al. "Exploration of the optimized portrait of omega-3 polyunsaturated fatty acids in treating depression: A meta-analysis of randomized-controlled trials." J Affect Disord. 2025. 36 RCTs. SMD = -0.26. Optimal: 1-1.5 g/day, EPA:DHA 1:1-2:1. PubMed
4. Blair C, et al. "Anti-inflammatory effects and safety of omega-3 fatty acids in haemodialysis: A systematic review and meta-analysis." Clin Nutr ESPEN. 2026. CRP reduction: SMD -0.62. PubMed
5. Omega-3 and sleep efficiency meta-analysis. 8 RCTs. Significant improvement vs control. 2024. PubMed
6. Du S, et al. "Does Fish Oil Have an Anti-Obesity Effect in Overweight/Obese Adults? A Meta-Analysis of Randomized Controlled Trials." PLoS One. 2015. 21 studies: no significant effect on body weight. PubMed
7. Lu H, et al. "Comparison of EPA and DHA&EPA on body weight, BMI, and lean body mass in cancer patients: a network meta-analysis." Support Care Cancer. 2025. Combined DHA+EPA improved body weight and BMI. PubMed
8. AHA/ACC guidelines recommend prescription omega-3s (icosapent ethyl) for persistent hypertriglyceridemia (≥150 mg/dL) as adjunct to statin therapy.
9. Dyall SC. "Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA." Front Aging Neurosci. 2015. DHA as primary structural brain omega-3. PubMed
10. Schuchardt JP, Hahn A. "Bioavailability of long-chain omega-3 fatty acids." Prostaglandins Leukot Essent Fatty Acids. 2013. Triglyceride form > ethyl ester for absorption. PubMed

Related Guides